Refine
Year of publication
Document Type
- Article (91)
- Preprint (50)
- Book (1)
- Conference Proceeding (1)
- Working Paper (1)
Language
- English (144)
Has Fulltext
- yes (144)
Is part of the Bibliography
- no (144) (remove)
Keywords
- Elastic scattering (3)
- Collectivity (2)
- Correlation (2)
- Diffraction (2)
- Polarization (2)
- RHIC (2)
- Shear viscosity (2)
- B-slope (1)
- Charge fluctuations (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Charmonia (1)
- Coalescence (1)
- Cold nuclear matter effects (1)
- Computerlinguistik (1)
- Critical point (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Dialog (1)
- Elliptic flow (1)
- Flow (1)
- Groomed jet radius (1)
- Hadronization (1)
- Heavy Ion Experiments (1)
- Heavy Quark Production (1)
- Heavy ion collisions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-ion (1)
- Heavy-ion collisions (1)
- Higher moments (1)
- Interference fragmentation function (1)
- J/ψ suppression (1)
- Jet substructure (1)
- Multiple parton interactions (1)
- Net-charge correlations (1)
- Net-charge fluctuations (1)
- Nonflow (1)
- Proton-proton collisions (1)
- Proton–proton collisions (1)
- QGP (1)
- Quarkonium (1)
- Relativistic heavy-ion collisions (1)
- STAR (1)
- SoftDrop (1)
- Spin alignment (1)
- Splitting function (1)
- Thermal model (1)
- Transversity (1)
- acute myeloid leukemia (1)
- cytarabine dose (1)
- elderly (1)
- p+p collisions (1)
Institute
- Physik (104)
- Frankfurt Institute for Advanced Studies (FIAS) (39)
- Extern (1)
- Medizin (1)
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1–3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1–7) plus daunorubicin (45 mg/m2 days 3–5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33–45] versus 55% (95% CI: 49–61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.